LTR Pharma (ASX:LTP) Ending Cash Position : A$1.73 Mil (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Ending Cash Position?

LTR Pharma's Ending Cash Position for the quarter that ended in Jun. 2023 was A$1.73 Mil.

LTR Pharma's quarterly Ending Cash Position increased from Jun. 2021 (A$0.15 Mil) to Jun. 2022 (A$1.91 Mil) but then declined from Jun. 2022 (A$1.91 Mil) to Jun. 2023 (A$1.73 Mil).

LTR Pharma's annual Ending Cash Position increased from Jun. 2021 (A$0.15 Mil) to Jun. 2022 (A$1.91 Mil) but then declined from Jun. 2022 (A$1.91 Mil) to Jun. 2023 (A$1.73 Mil).

LTR Pharma Ending Cash Position Historical Data

The historical data trend for LTR Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Ending Cash Position Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Ending Cash Position

0.15

1.91

1.73

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Ending Cash Position	0.15	1.91	1.73

LTR Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

LTR Pharma's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.913	+	-0.184
	=	1.73

LTR Pharma's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.913	+	-0.184
	=	1.73

LTR Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines